iNtRON Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

iNtRON Biotechnology şirketinin toplam hissedar öz sermayesi ₩93.0B ve toplam borcu ₩0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₩94.8B ve ₩1.9B dir.

Anahtar bilgiler

Borç/özkaynak oranı

₩0

Borç

Faiz karşılama oranı	n/a
Nakit	₩56.51b
Eşitlik	₩92.97b
Toplam yükümlülükler	₩1.88b
Toplam varlıklar	₩94.85b

Son finansal sağlık güncellemeleri

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: A048530 'nin kısa vadeli varlıkları ( ₩59.6B ) kısa vadeli yükümlülüklerini ( ₩1.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: A048530 şirketinin kısa vadeli varlıkları ( ₩59.6B ) uzun vadeli yükümlülüklerini ( ₩493.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: A048530 borçsuzdur.

Borcun Azaltılması: A048530 şirketinin 5 yıl önce borç/öz sermaye oranı 25.2% iken borcu yok.

Borç Kapsamı: A048530 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: A048530 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

iNtRON Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Full year 2023 earnings released: ₩292 loss per share (vs ₩168 profit in FY 2022)

Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

iNtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome

Full year 2022 earnings released: EPS: ₩168 (vs ₩288 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

iNtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Price target decreased to ₩16,400

iNtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Develops New CRISPR/Cas Technology Specific for Bacteriophage as PHAGERUS® Platform

iNtRON Biotechnology, Inc. Confirms Efficacy of Cdl200 Against CDI Clinical Isolates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology Completes GLP-TOX Studies of BAL200

Price target decreased to ₩16,400

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology, Inc. announced that it has received KRW 40 billion in funding

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc., Annual General Meeting, Mar 25, 2021

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

New 90-day high: ₩23,000

Investor sentiment improved over the past week

Market bids up stock over the past week

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

New 90-day high: ₩17,050

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

New 90-day low: ₩13,800

New 90-day high - ₩18,100

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin